Robert Adelman - Profile and Investment Details

Investor Profile

Robert Adelman is a Venture Capital, Private Equity Firm, Investor based in San Francisco, California, United States with a diverse investment portfolio that includes companies such as Attralus, Aurinia Pharmaceuticals, Labrys Biologics, Adaptimmune, Metacrine, Seragon Pharmaceuticals, NorthSea Therapeutics, Solstice Biologics, Outlook Therapeutics, Stargazer Pharmaceuticals, Heart Metabolics, Turning Point Therapeutics, Precision BioSciences, Aeovian Pharmaceuticals, Akero Therapeutics, Harmony BiosciencesRayzeBio, Ventyx Biosciences, Elevation Oncology, ALX Oncology, Impel NeuroPharma, Checkmate Pharmaceuticals, Apellis Pharmaceuticals, Tallac Therapeutics, CryoCor, Bellicum Pharmaceuticals, Cytos, Artiva Biotherapeutics, Stem Cell Therapeutics, VYNE Therapeutics, Cidara Therapeutics, Arrakis Therapeutics, INBRACE, Pharvaris, Neurogastrx, NFlection Therapeutics, Aragon Pharmaceuticals, Fog Pharmaceuticals, . Over time, Robert Adelman has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Robert Adelman is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Patient Care, Health Care, Drug Discovery, Autoimmune Diseases, Wellness, Women Founded, Life Science, Medical Technologies, Manufacturing, Biotechnology, Drug Development, Clinical Trials, Vaccines, Medical, B2B, Therapeutics, Pharmaceuticals, Risk Management may find it worthwhile to explore potential connections with Robert Adelman, as their portfolio suggests a familiarity and interest in this area.

Understanding Robert Adelman’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.